Description: Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist (IC50=36 nM in LNCaP) that activates autophagy, exhibits antitumor activity, and is commonly used in treating desmoplasia-resistant prostate cancer. Target: Autophagy, Androgen Receptor. Smiles:...

MDV 3100 is a non-steroidal androgen receptor antagonist (IC50 = 36 nM). It reduces the efficiency of nuclear translocation of the androgen receptor and impairs both its binding to DNA and the recruitment of coactivators. It is orally available and induces tumor regression in mouse models of castration-resistant...